MGX Key Statistics, Chart & Performance
The current stock price of MGX is 1.7398 USD. In the past month the price decreased by -7.39%. In the past year, price decreased by -45.12%.
MGX Technical Analysis
MGX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MGX. While MGX has a great health rating, there are worries on its profitability.
MGX Financial Highlights
Over the last trailing twelve months MGX reported a non-GAAP Earnings per Share(EPS) of -2.4. The EPS increased by 4.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -35.79% | ||
| ROE | -49.73% | ||
| Debt/Equity | 0 |
MGX Forecast & Estimates
9 analysts have analysed MGX and the average price target is 9.52 USD. This implies a price increase of 447.19% is expected in the next year compared to the current price of 1.7398.
For the next year, analysts expect an EPS growth of 9.05% and a revenue growth -46.01% for MGX
MGX Ownership
About MGX
Company Profile
Metagenomi, Inc. is a precision genetic medicines company, which engages in the business of developing next generation gene-editing technologies and therapies. The company is headquartered in Emeryville, California and currently employs 124 full-time employees. The company went IPO on 2024-02-09. The firm is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). The company has also developed a modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. The firm uses artificial intelligence and its metagenomics platform to develop curative genetic medicines.
Company Info
METAGENOMI THERAPEUTICS INC
5959 Horton St, Floor 7
Emeryville CALIFORNIA US
Employees: 124
Phone: 15108714880
METAGENOMI THERAPEUTICS INC / MGX FAQ
Can you describe the business of METAGENOMI THERAPEUTICS INC?
Metagenomi, Inc. is a precision genetic medicines company, which engages in the business of developing next generation gene-editing technologies and therapies. The company is headquartered in Emeryville, California and currently employs 124 full-time employees. The company went IPO on 2024-02-09. The firm is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). The company has also developed a modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. The firm uses artificial intelligence and its metagenomics platform to develop curative genetic medicines.
What is the stock price of METAGENOMI THERAPEUTICS INC today?
The current stock price of MGX is 1.7398 USD. The price increased by 6.74% in the last trading session.
Does MGX stock pay dividends?
MGX does not pay a dividend.
How is the ChartMill rating for METAGENOMI THERAPEUTICS INC?
MGX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is MGX stock listed?
MGX stock is listed on the Nasdaq exchange.
Is METAGENOMI THERAPEUTICS INC (MGX) expected to grow?
The Revenue of METAGENOMI THERAPEUTICS INC (MGX) is expected to decline by -46.01% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the number of employees for METAGENOMI THERAPEUTICS INC?
METAGENOMI THERAPEUTICS INC (MGX) currently has 124 employees.